Comparative serum proteomic analysis identified afamin as a downregulated protein in papillary thyroid carcinoma patients with non-131I-avid lung metastases.
Comparative serum proteomic analysis identified afamin as a downregulated protein in papillary thyroid carcinoma patients with non-131I-avid lung metastases.
复制标题
比较血清蛋白质组学分析确定 afamin 是具有非 131I 活跃肺转移的甲状腺乳头状癌患者中的下调蛋白
DOI：
10.1097/mnm.0000000000000001
复制
发表时间：
2013-12
影响因子：
1.5
通讯作者：
Luo QY
中科院分区：
文献类型：
--
作者：
Song HJ;Xue YL;Qiu ZL;Luo QY
背景分化型甲状腺癌（DTC）转移灶摄取~（131）I能力的丧失已成为放射性碘治疗的主要障碍。然而，没有有效的方法来筛选转移瘤的131 I摄取能力。通过血清蛋白质组学方法鉴定差异表达蛋白，有助于我们对DTC去分化机制的理解。材料与方法血清标本取自甲状腺乳头状癌非~（131）I亲合肺转移和~（131）I亲合肺转移患者。采用双向凝胶电泳进行差异蛋白质分析。通过基质辅助激光解吸/电离飞行时间质谱法鉴定两组之间表达差异的候选蛋白质点，并通过蛋白质印迹法进行验证。结果我们发现，afamin在甲状腺乳头状癌非131 I-亲合性肺转移患者血清中表达下调。结论Afamin可作为DTC转移灶摄取131 I能力早期筛查的血清标志物，对指导放射性碘治疗有一定价值。
BackgroundThe loss of 131I uptake ability in metastases from differentiated thyroid carcinoma (DTC) is becoming a major obstacle in radioiodine treatment. However, there is no effective way to screen for 131I uptake ability in metastases. The identification of differentially expressed proteins by serum proteomics may contribute to our understanding of the mechanisms underlying the dedifferentiation of DTC. Materials and methodsSerum samples were obtained from papillary thyroid carcinoma patients with non-131I-avid lung metastases and 131I-avid lung metastases. Differential protein analysis was performed using two-dimensional gel electrophoresis. Candidate protein spots showing differences in expression between the two groups were identified by means of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and were validated by western blotting. ResultsWe found that afamin is downregulated in the serum of papillary thyroid carcinoma patients with non-131I-avid lung metastases. ConclusionAfamin may be a potential serum biomarker for early screening of 131I uptake ability in DTC metastases and could therefore be of value in guiding radioiodine treatment decisions.